Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A

Trial Profile

Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Jul 2014

At a glance

  • Drugs Tadalafil (Primary)
  • Indications Diabetic cardiomyopathy; Type 2 diabetes mellitus
  • Focus Biomarker; Therapeutic Use
  • Acronyms RECOGITO
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top